{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:22:37Z","timestamp":1766172157161,"version":"3.48.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31500282"],"award-info":[{"award-number":["31500282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004572","name":"National Health and Family Planning Commission of the Peoples Republic of China","doi-asserted-by":"publisher","award":["2017ZX09304022"],"award-info":[{"award-number":["2017ZX09304022"]}],"id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.heliyon.2023.e17905","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:46:41Z","timestamp":1688212001000},"page":"e17905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with increased risk of lurasidone-induced somnolence: Two case-control studies based on one bioequivalence trial in healthy volunteers"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-5293","authenticated-orcid":false,"given":"Hengyi","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaifu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e17905_bib1","volume":"1","author":"Kahn","year":"2015","journal-title":"Schizophrenia. Nat Rev Dis Primers."},{"year":"2013","series-title":"Latuda (Lurasidone Hydrochloride) Tablets [prescribing Information]","key":"10.1016\/j.heliyon.2023.e17905_bib2"},{"year":"2014","series-title":"Summary of Product Characteristics: Latuda","key":"10.1016\/j.heliyon.2023.e17905_bib3"},{"year":"2020","series-title":"Summary of Opinion (Post Authorisation): Latuda","key":"10.1016\/j.heliyon.2023.e17905_bib4"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e17905_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e17905_bib6","first-page":"6002","article-title":"Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement","volume":"17","author":"He","year":"2018","journal-title":"Mol. Med. Rep."},{"year":"2022","series-title":"Latuda (Lurasidone Hydrochloride) Tablets [prescribing Information]","key":"10.1016\/j.heliyon.2023.e17905_bib7"},{"issue":"1\u20133","key":"10.1016\/j.heliyon.2023.e17905_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.heliyon.2023.e17905_bib9","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.2147\/IJGM.S320611","article-title":"Impact of lurasidone and other antipsychotics on body weight: real-world, retrospective, comparative study of 15,323 adults with schizophrenia","volume":"14","author":"Pochiero","year":"2021","journal-title":"Int. J. Gen. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e17905_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e17905_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic drug-induced somnolence: incidence, mechanisms, and management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e17905_bib12","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4088\/JCP.09r05535gre","article-title":"Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics","volume":"72","author":"Gao","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e17905_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JCP.0000000000000867","article-title":"Longer-term effectiveness and tolerability of adjunctive open lurasidone in patients with bipolar disorder","volume":"38","author":"Miller","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e17905_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11126-011-9185-z","article-title":"Antipsychotic-induced somnolence in mothers with schizophrenia","volume":"83","author":"Seeman","year":"2012","journal-title":"Psychiatr. Q."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e17905_bib15","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.clinthera.2015.11.001","article-title":"Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders","volume":"37","author":"Findling","year":"2015","journal-title":"Clin. Therapeut."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e17905_bib16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40261-017-0546-8","article-title":"Single- and multiple-dose pharmacokinetics, safety and tolerability of lurasidone in healthy Chinese subjects","volume":"37","author":"Hu","year":"2017","journal-title":"Clin. Drug Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e17905_bib17","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1192\/j.eurpsy.2021.30","article-title":"Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: a pooled post hoc analysis of double-blind, placebo-controlled 6-week studies","volume":"64","author":"Costamagna","year":"2021","journal-title":"Eur. Psychiatr."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e17905_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e17905_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e17905_bib20","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study","volume":"77","author":"Loebel","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e17905_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12352","article-title":"Lurasidone in the treatment of schizophrenia: results of a double-blind, placebo-controlled trial in Asian patients","volume":"11","author":"Higuchi","year":"2019","journal-title":"Asia Pac. Psychiatr."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e17905_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/bmc.3651","article-title":"LC-MS\/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study","volume":"30","author":"Katteboina","year":"2016","journal-title":"Biomed. Chromatogr."},{"journal-title":"National Medical Products Administration of China","article-title":"The list of drugs for which approval documents were obtained on 10 June 2022","year":"2022","key":"10.1016\/j.heliyon.2023.e17905_bib23"},{"year":"2017","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) (Version 5.0)","key":"10.1016\/j.heliyon.2023.e17905_bib24"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e17905_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","article-title":"Quantification of sleepiness: a new approach","volume":"10","author":"Hoddes","year":"1973","journal-title":"Psychophysiology"},{"year":"2014","series-title":"Safety Monitoring of Medicinal Products: Guidelines for Setting up and Running a Pharmacovigilance Centre","key":"10.1016\/j.heliyon.2023.e17905_bib26"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e17905_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e17905_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/JCP.0b013e3182917f3f","article-title":"Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia","volume":"33","author":"Gao","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e17905_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.clinthera.2009.03.002","article-title":"Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects","volume":"31","author":"Datto","year":"2009","journal-title":"Clin. Therapeut."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e17905_bib30","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.clinthera.2012.09.002","article-title":"Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study","volume":"34","author":"Riesenberg","year":"2012","journal-title":"Clin. Therapeut."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e17905_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-1241.2010.02587.x","article-title":"Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic","volume":"65","author":"Citrome","year":"2011","journal-title":"Int. J. Clin. Pract."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023051137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023051137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:11:09Z","timestamp":1766171469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023051137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2405844023051137"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17905","relation":{},"ISSN":["2405-8440"],"issn-type":[{"type":"print","value":"2405-8440"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with increased risk of lurasidone-induced somnolence: Two case-control studies based on one bioequivalence trial in healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e17905"}}